Omeros Valuation
Is 0KBU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0KBU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0KBU's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0KBU's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0KBU?
Key metric: As 0KBU is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 0KBU's PB Ratio? | |
|---|---|
| PB Ratio | -4.1x |
| Book | -US$154.17m |
| Market Cap | US$632.23m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -5.5x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 0KBU's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.9x | ||
FUM Futura Medical | 12.8x | 188.3% | UK£99.6m |
APH Alliance Pharma | 1.1x | 69.7% | UK£246.0m |
HCM HUTCHMED (China) | 4x | 47.9% | UK£2.4b |
AGY Allergy Therapeutics | 65.7x | 32.8% | UK£243.6m |
0KBU Omeros | n/a | 39.1% | US$632.2m |
Price-To-Book vs Peers: 0KBU has negative equity and a Price-To-Book Ratio (-4.1x) compared to the peer average (20.9x).
Price to Book Ratio vs Industry
How does 0KBU's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?
Price-To-Book vs Industry: 0KBU has negative equity and a Price-To-Book Ratio (-4.1x) compared to the European Pharmaceuticals industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is 0KBU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -4.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 0KBU's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€62.90
7D
1.5%
1Y
14.6%
Formycon
€827.2m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€47.10
7D
4.0%
1Y
-23.5%
Regeneron Pharmaceuticals
US$79.4b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$748.39
7D
-1.7%
1Y
-6.3%